central nervous system

Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.

Authors: Blennow K, Fuchs D, Gisslén M, Mellgren Å, Nilsson S, Yilmaz A, Zetterberg H

Journal: Infectious diseases

Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low-level persistent immune activation in the central nervous system (CNS). There have been concerns regarding the CNS efficacy of tenofovir alafenamide fumarate (TAF) because of its […]

Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals?

Authors: Allsop JM, Cox JI, Garvey L, Grover VP, Main J, Scotney E, Taylor-Robinson SD, Thomson EC, Winston A, Wylezinska M, Yerrakalva D

Journal: Journal of Viral Hepatitis

Central nervous system (CNS) manifestations of chronic hepatitis C virus (HCV) and chronic human immune deficiency virus-1 (HIV-1) infections have been reported, but the impact of acute HCV infection on the CNS is unknown. A total […]

Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer’s disease: a preliminary study.

Authors: Ames D, Bourgeat P, Bush AI, Ellis KA, Harrington K, Laws SM, Lim YY, Martins RN, Maruff P, Masters CL, Pietrzak RH, Rowe CC, Villemagne VL

Journal: Public Library of Science One

OBJECTIVE: Cross-sectional genetic association studies have reported equivocal results on the relationship between the brain-derived neurotrophic factor (BDNF) Val66Met and risk of Alzheimer’s disease (AD). As AD is a neurodegenerative disease, genetic influences may become clearer […]

Back to Publications